A phase II study of combined adriamycin, L-PAM, and methotrexate with citrovorum factor rescue in advanced ovarian carcinomas.
In a phase II study of combined adriamycin, L-PAM, and methotrexate with citrovorum factor rescue, 14 of 15 patients with primary advanced or recurrent ovarian malignant tumors obtained an objective remission. In remission, all patients improved their quality of life. So far the median duration of remission is 5+ months for the complete responders and 7 months for the partial responders. Myelosuppression of varying severity occurred in 93% of the courses. The regimen proved highly effective, although toxic in some advanced patients.
D000328:Adult; D000368:Aged; D003536:Cystadenocarcinoma / Q000188:drug therapy; D003537:Cystadenoma / Q000188:drug therapy; D004317:Doxorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006106:Granulosa Cell Tumor / Q000188:drug therapy; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use*; D008558:Melphalan / Q000627:therapeutic use*; D008649:Mesonephroma / Q000188:drug therapy; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D004317:Doxorubicin; D008558:Melphalan; D002955:Leucovorin; D008727:Methotrexate